Search

Charles E Zeilig

from Tucson, AZ
Age ~81
Get Report
Also known as:
Charles E Zelig, Charles Zeilig Elliott
Related to:
Marcella Joan Lively, 75Neil CyrusJohn Christensen, 64Katherine Holsteen, 35Danette Morgan, 63Nell Cyrus
Connected to:
Raymond K Zeillmann, 81Lucille J Zeilman, 79Fred J Zeilner, 69Jacob F Zeimantz, 40Darla J Zeimet, 68Richard E Zeimet, 57Greta P Zeimetz, 62David N Zein, 56El Zein, 38Hilmi R Zein, 58

Charles Zeilig Phones & Addresses

  • Tucson, AZ
  • 1069 131St Ave, Denver, CO 80241 (303) 333-5353
  • 134 Monaco St, Denver, CO 80224 (303) 333-5353
  • 1595 Hudson St, Denver, CO 80222 (303) 758-7750 (303) 758-8846
  • Aurora, CO
  • Thornton, CO

Resumes

Resumes

Charles Zeilig Photo 1

Chief Scientific Officer At Cyclegen, Inc.

View page
Position:
Founder and Chief Scientific Officer at CycleGen, Inc., Chief Scientific Officer at CycleGen, Inc.
Location:
Greater Denver Area
Industry:
Research
Work:
CycleGen, Inc. - Denver-Boulder since Jun 2005
Founder and Chief Scientific Officer
CycleGen, Inc. since Jun 2005
Chief Scientific Officer
The HiFi Doctor - Greater Denver Area Aug 2010 - Jan 2013
Owner
Education:
University of Colorado at Boulder 2005 - 2008
University of Colorado School of Medicine 1977 - 1981
Vanderbilt University School of Medicine 1970 - 1975
PhD, Physiology and Molecular Oncology University of Windsor 1967 - 1969
M.Sc., Biochemistry & Zoology
Skills:
Budgets
Testing
Consumer Electronics
Project Planning
Electronics
Manufacturing
Sales Management
Product Development
Project Management
Business Development
Strategy
Strategic Planning
Product Launch
Competitive Analysis
Product Management
Marketing Strategy
Product Marketing
Cross-functional Team Leadership
Sound
Business Strategy
R&D
Start-ups
New Business Development
Team Leadership
AV
Sales
Marketing
Psychoacoustics
Strategic Partnerships
Team Building
Acoustics
Digital Signal Processors
Entrepreneurship
Research
Audio Processing
Signal Processing
Program Management
Digital Signal Processing
Medical Devices
International Sales
Sales Operations
Streaming Media
Business Planning
System Design
E-commerce
Executive Management
P&L Management
Leadership
Audio Engineering
Charles Zeilig Photo 2

Owner

View page
Location:
Denver, CO
Industry:
Research
Work:
The Hifi Doctor
Owner
Cyclegen
Founder, Vice President, and Chief Strategy Officer
Education:
University of Colorado Boulder 2005 - 2008
University of Colorado School of Medicine 1977 - 1981
University of Minnesota 1975 - 1976
Vanderbilt University School of Medicine 1970 - 1975
Doctorates, Doctor of Philosophy, Physiology University of Windsor 1966 - 1968
Master of Science, Masters, Molecular Biology, Biochemistry University of Windsor 1964 - 1967
Bachelors, Bachelor of Science, Biochemistry, Zoology
Skills:
Budgets
Testing
Consumer Electronics
Project Planning
Electronics
Manufacturing
Sales Management
Product Development
Project Management
Business Development
Strategy
Strategic Planning
Product Launch
Competitive Analysis
Product Management
Marketing Strategy
Product Marketing
Cross Functional Team Leadership
Sound
Business Strategy
R&D
Start Ups
New Business Development
Team Leadership
Av
Sales
Marketing
Psychoacoustics
Strategic Partnerships
Team Building
Acoustics
Digital Signal Processors
Entrepreneurship
Research
Audio Processing
Signal Processing
Program Management
Digital Signal Processing
Medical Devices
International Sales
Sales Operations
Streaming Media
Business Planning
System Design
E Commerce
Executive Management
P&L Management
Leadership
Audio Engineering
Video Conferencing
Languages:
French
Charles Zeilig Photo 3

Founder, Chief Scientific Officer, And Vice President

View page
Location:
Denver, CO
Industry:
Biotechnology
Work:
Cyclegen May 2005 - May 2005
Founder, Chief Scientific Officer, and Vice President
Skills:
Molecular Biology
Science
Charles Zeilig Photo 4

Charles Zeilig

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Charles E. Zeilig
Principal
The Hifi Doctor-Rx for Better Audio
Ret Misc Merchandise
1069 E 131 Dr, Denver, CO 80241

Publications

Us Patents

Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis

View page
US Patent:
20110098232, Apr 28, 2011
Filed:
Oct 25, 2010
Appl. No.:
12/911723
Inventors:
Charles E. Zeilig - Thornton CO, US
International Classification:
A61K 38/13
A61P 35/00
A61K 38/02
US Classification:
514 192
Abstract:
Available evidence indicates that tumor cells exhibit consistent abnormalities in Calcium influx and intracellular storage of sequestered Calcium when compared to normal cells. The present invention provides clinical methods by which such differences are exploited to induce Apoptosis selectively in tumor cells while sparing normal cells. These methods are based upon employing drugs that, acting alone or in synergistic combinations, produce an increase in intracellular Calcium loading such that either or both of two major Apoptotic pathways are triggered to produce selective killing of malignant cells. Since the invention is based upon fundamental cell cycle requirements, to the extent that Calcium handling abnormalities are a general characteristic of the malignant state, the methods presented here are widely applicable regardless of tissue of origin and degree of cellular de-differentiation.

Intracellular Calcium Modulation For Cancer Treatment

View page
US Patent:
20140065246, Mar 6, 2014
Filed:
Nov 6, 2013
Appl. No.:
14/073850
Inventors:
Charles E. Zeilig - Thornton CO, US
International Classification:
A61K 38/13
A61K 31/164
A61K 31/215
A61K 31/19
A61K 33/06
A61K 31/59
A61K 31/6615
A61K 31/18
A61K 31/426
US Classification:
424682, 514603, 514510, 514370, 514 199
Abstract:
Tumor cells exhibit consistent abnormalities in calcium regulation. The present disclosure teaches methods by which such differences are exploited to induce Apoptosis selectively in tumor/cancer cells while sparing normal cells. These methods are based upon employing drugs that, acting in synergistic combinations, trigger selective killing of malignant cells. Since the invention is based upon fundamental cell cycle requirements, to the extent that calcium handling abnormalities are a general characteristic of the malignant state, the methods presented here are widely applicable regardless of tissue of origin and degree of cellular de-differentiation.

Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis

View page
US Patent:
20070054874, Mar 8, 2007
Filed:
Jun 1, 2004
Appl. No.:
10/558079
Inventors:
Charles Zeilig - Denver CO, US
International Classification:
A61K 31/7076
A61K 31/522
A61K 31/366
A61K 31/554
A61K 31/4745
US Classification:
514045000, 514211070, 514453000, 514291000
Abstract:
Disclosed are clinical methods for inducing apoptosis selectively in tumor cells while sparing normal cells. These methods employ drugs that, acting alone or in synergistic combinations, produce an increase in intracellular Calcium loading such that either or both of two major apoptotic pathways are triggered to produce selective killing of malignant cells. The methods disclosed are widely applicable regardless of tissue of origin and degree of cellular de-differentiation.

Methods For The Selective Treatment Of Tumors By Calcium-Mediated Induction Of Apoptosis

View page
US Patent:
20170246241, Aug 31, 2017
Filed:
May 15, 2017
Appl. No.:
15/595805
Inventors:
Charles E. Zeilig - Aurora CO, US
International Classification:
A61K 38/13
A61K 31/164
A61K 31/215
A61K 31/19
A61K 33/06
A61K 31/59
A61K 31/6615
A61K 31/18
A61K 31/426
Abstract:
Tumor cells exhibit consistent abnormalities in calcium regulation. The present disclosure teaches methods by which such differences are exploited to induce Apoptosis selectively in tumor/cancer cells while sparing normal cells. These methods are based upon employing drugs that, acting in synergistic combinations, trigger selective killing of malignant cells. Since the invention is based upon fundamental cell cycle requirements, to the extent that calcium handling abnormalities are a general characteristic of the malignant state, the methods presented here are widely applicable regardless of tissue of origin and degree of cellular de-differentiation.
Control profile
Charles E Zeilig from Tucson, AZ, age ~81 Get Report